However, patients with a high proportion of AXL+ melanoma cells (regardless of MITF expression) before therapy show a trend toward worse survival compared with patients with low pre-treatment AXL+ levels (Supplementary Figure S6D, available at https://doi.org/10.1016/j.iotech.2024.101009). This evidence concerns the gene MITF and melanoma.